Back to search
FDAFDA · Food and drugs·Recall number D-0127-2020

Sandoz Ranitidine Hydrochloride Capsules 150mg 60 Capsules Rx Only Manufactured by Sandoz Inc. Princeton, NJ Product of India NDC 0781-2855-60

Published October 16, 2019 · Recall initiated: September 23, 2019

Summary

FDA records drug Class II recall D-0127-2020, published October 16, 2019 and initiated September 23, 2019. Recalling firm: Sandoz, Inc; Status: Terminated; Reported quantity: 100,314 bottles; Lot: HC9266 4/30/2020 HD1865 4/30/2020 HP9441 9/30/2020 JK7994 8/31/2021 JK8659 8/31/2021. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations: Detection of a trace amount of an unexpected impurity, N-nitrosodimethylamine (NDMA).

What to do

Voluntary: Firm initiated · Press Release

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Sandoz, Inc
Distributor
U.S. Nationwide
Lot
HC9266 4/30/2020 HD1865 4/30/2020 HP9441 9/30/2020 JK7994 8/31/2021 JK8659 8/31/2021
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Sandoz Ranitidine Hydrochloride Capsules 150mg 60 Capsules Rx Only Manufactured by Sandoz Inc. Princeton, NJ Product of India NDC 0781-2855-60 recalled?

Yes. FDA published recall D-0127-2020 on October 16, 2019. Reported hazard: CGMP Deviations: Detection of a trace amount of an unexpected impurity, N-nitrosodimethylamine (NDMA).

What should I do if I have this product?

Voluntary: Firm initiated · Press Release